REYON Pharmaceutical Co., Ltd. (102460.KS)
KRW 13020.0
(-2.18%)
KRW 13020.0
(-2.18%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 76.81 Billion KRW | -6.01% |
| 2022 | 81.72 Billion KRW | 2.88% |
| 2021 | 79.43 Billion KRW | 9.44% |
| 2020 | 72.58 Billion KRW | -2.26% |
| 2019 | 74.26 Billion KRW | 8.37% |
| 2018 | 68.52 Billion KRW | -5.68% |
| 2017 | 72.65 Billion KRW | 3.32% |
| 2016 | 70.31 Billion KRW | 4.98% |
| 2015 | 66.98 Billion KRW | 5.63% |
| 2014 | 63.41 Billion KRW | -0.12% |
| 2013 | 63.49 Billion KRW | -5.68% |
| 2012 | 67.31 Billion KRW | -15.01% |
| 2011 | 79.21 Billion KRW | 1.97% |
| 2010 | 77.67 Billion KRW | 36.12% |
| 2009 | 57.06 Billion KRW | 33.65% |
| 2008 | 42.69 Billion KRW | 28.73% |
| 2007 | 33.16 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 18.45 Billion KRW | -2.42% |
| 2024 Q2 | 17 Billion KRW | -7.87% |
| 2023 Q4 | 18.91 Billion KRW | 3.14% |
| 2023 Q2 | 20.4 Billion KRW | -2.17% |
| 2023 Q3 | 18.33 Billion KRW | -10.13% |
| 2023 FY | 76.81 Billion KRW | -6.01% |
| 2023 Q1 | 20.85 Billion KRW | 9.68% |
| 2022 Q4 | 19.01 Billion KRW | -7.62% |
| 2022 Q3 | 20.58 Billion KRW | -6.78% |
| 2022 Q1 | 20.05 Billion KRW | 0.65% |
| 2022 FY | 81.72 Billion KRW | 2.88% |
| 2022 Q2 | 22.07 Billion KRW | 10.09% |
| 2021 Q3 | 20.06 Billion KRW | 0.13% |
| 2021 Q1 | 19.41 Billion KRW | 3.02% |
| 2021 FY | 79.43 Billion KRW | 9.44% |
| 2021 Q2 | 20.03 Billion KRW | 3.18% |
| 2021 Q4 | 19.92 Billion KRW | -0.68% |
| 2020 Q3 | 18.48 Billion KRW | 6.93% |
| 2020 Q2 | 17.28 Billion KRW | -3.78% |
| 2020 Q1 | 17.96 Billion KRW | -2.66% |
| 2020 FY | 72.58 Billion KRW | -2.26% |
| 2020 Q4 | 18.84 Billion KRW | 1.97% |
| 2019 Q2 | 18.13 Billion KRW | -4.88% |
| 2019 Q4 | 18.45 Billion KRW | -0.82% |
| 2019 FY | 74.26 Billion KRW | 8.37% |
| 2019 Q1 | 19.06 Billion KRW | 26.47% |
| 2019 Q3 | 18.6 Billion KRW | 2.62% |
| 2018 Q3 | 17.18 Billion KRW | -6.06% |
| 2018 FY | 68.52 Billion KRW | -5.68% |
| 2018 Q4 | 15.07 Billion KRW | -12.3% |
| 2018 Q2 | 18.29 Billion KRW | 1.82% |
| 2018 Q1 | 17.96 Billion KRW | 8.25% |
| 2017 FY | 72.65 Billion KRW | 3.32% |
| 2017 Q4 | 16.59 Billion KRW | -11.15% |
| 2017 Q3 | 18.68 Billion KRW | 3.57% |
| 2017 Q2 | 18.03 Billion KRW | -6.67% |
| 2017 Q1 | 19.32 Billion KRW | 6.65% |
| 2016 Q3 | 17.26 Billion KRW | -0.74% |
| 2016 FY | 70.31 Billion KRW | 4.98% |
| 2016 Q4 | 18.12 Billion KRW | 4.95% |
| 2016 Q2 | 17.39 Billion KRW | -0.74% |
| 2016 Q1 | 17.52 Billion KRW | -8.84% |
| 2015 Q3 | 16.13 Billion KRW | 3.93% |
| 2015 Q4 | 19.22 Billion KRW | 19.13% |
| 2015 Q2 | 15.52 Billion KRW | -3.49% |
| 2015 Q1 | 16.09 Billion KRW | 6.67% |
| 2015 FY | 66.98 Billion KRW | 5.63% |
| 2014 Q4 | 15.08 Billion KRW | -2.99% |
| 2014 Q2 | 16.49 Billion KRW | 1.24% |
| 2014 Q1 | 16.29 Billion KRW | -1.04% |
| 2014 FY | 63.41 Billion KRW | -0.12% |
| 2014 Q3 | 15.54 Billion KRW | -5.72% |
| 2013 Q1 | 14.83 Billion KRW | -16.69% |
| 2013 Q2 | 16.95 Billion KRW | 14.27% |
| 2013 Q4 | 16.46 Billion KRW | 7.95% |
| 2013 Q3 | 15.24 Billion KRW | -10.05% |
| 2013 FY | 63.49 Billion KRW | -5.68% |
| 2012 FY | 67.31 Billion KRW | -15.01% |
| 2012 Q4 | 17.8 Billion KRW | -1.0% |
| 2012 Q3 | 17.98 Billion KRW | 2.35% |
| 2012 Q2 | 17.57 Billion KRW | 25.96% |
| 2012 Q1 | 13.95 Billion KRW | -30.82% |
| 2011 Q2 | 18.29 Billion KRW | -9.19% |
| 2011 Q1 | 20.14 Billion KRW | -4.67% |
| 2011 Q3 | 20.6 Billion KRW | 12.6% |
| 2011 Q4 | 20.16 Billion KRW | -2.1% |
| 2011 FY | 79.21 Billion KRW | 1.97% |
| 2010 Q3 | 20.3 Billion KRW | 7.29% |
| 2010 FY | 77.67 Billion KRW | 36.12% |
| 2010 Q2 | 18.92 Billion KRW | 0.0% |
| 2010 Q4 | 21.13 Billion KRW | 4.07% |
| 2009 FY | 57.06 Billion KRW | 33.65% |
| 2008 FY | 42.69 Billion KRW | 28.73% |
| 2007 FY | 33.16 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -65.183% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 78.902% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | 61.376% |
| HANDOK Inc. | 151.36 Billion KRW | 49.25% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | -14.271% |
| Yuhan Corporation | 564.5 Billion KRW | 86.392% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | 76.159% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -223.486% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 90.81% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | -2.37% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 61.39% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -88.977% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | 18.724% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | 45.463% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -65.183% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -121.278% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 737.729% |
| JW Holdings Corporation | 446.15 Billion KRW | 82.782% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | 62.986% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 88.278% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 77.115% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | 2.291% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | -2.1% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | -6.38% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | 58.209% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -65.183% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | 73.97% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 88.729% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 77.115% |
| Yuhan Corporation | 564.5 Billion KRW | 86.392% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | 61.938% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | -8.288% |
| Suheung Co., Ltd. | 99.02 Billion KRW | 22.427% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 77.115% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | 47.346% |
| Korea United Pharm Inc. | 173.48 Billion KRW | 55.721% |
| CKD Bio Corp. | 5.01 Billion KRW | -1433.208% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | 69.784% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | 58.279% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | 21.714% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | 2.291% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 79.322% |
| Boryung Corporation | 333.26 Billion KRW | 76.95% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | -53.497% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 61.39% |
| JW Lifescience Corporation | 51.32 Billion KRW | -49.67% |